HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

August 20, 2025

Study Completion Date

June 30, 2026

Conditions
HIV Associated Lymphoma
Interventions
BIOLOGICAL

HST-NEETs

HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10\^7/m\^2 cells between 3 Days and 7 Days post-ASCT.

BIOLOGICAL

Bone Marrow Transplant

Day 0 is the day of bone marrow transplantation.

Trial Locations (11)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan Kettering (MSKCC), New York

19104

University of Pennsylvania, Philadelphia

20057

Georgetown, Washington D.C.

21231

Johns Hopkins University, Baltimore

30342

Northside, Atlanta

33612

H. Lee Moffitt Cancer Center, Tampa

60612

University of Illinois, Chicago

77030

Baylor College of Medicine, Houston

MD Anderson, Houston

91010

City of Hope National Medical Center, Duarte

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Marrow Donor Program

OTHER

collaborator

Children's National Research Institute

OTHER

lead

Catherine Bollard

NIH